|
Valoración de DCF de Bone Biologics Corporation (BBLG)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Bone Biologics Corporation (BBLG) Bundle
Diseñada para la precisión, nuestra calculadora DCF (BBLG) le permite evaluar la valoración de Bone Biologics Corporation utilizando datos financieros del mundo real, junto con una flexibilidad completa para modificar todos los parámetros esenciales para mejorar las proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -2.4 | -.8 | .0 | .0 | .5 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | 1.1 | 3.7 | 9.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.4 | -.8 | -1.1 | -3.7 | -8.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .0 | .0 | 6.7 | 7.5 | 3.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | -.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .0 | .5 | .1 | .1 | .4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.4 | -.8 | -1.1 | 1.7 | -8.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2.4 | -.4 | -.4 | 6.0 | .2 | -.4 | .0 | .0 | .0 | .0 |
| WACC, % | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 | 7.92 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 3 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | 10.23 |
What You Will Get
- Real BBLG Financial Data: Pre-filled with Bone Biologics Corporation’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Bone Biologics Corporation’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Bone Biologics Corporation’s (BBLG) historical financials and projected forecasts.
- Customizable Assumptions: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Analysis: Instantly view the recalculated intrinsic value of Bone Biologics Corporation (BBLG).
- Intuitive Visualizations: Dashboard charts present valuation outcomes and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Bone Biologics Corporation (BBLG).
- Step 2: Review the pre-filled financial data and forecasts for Bone Biologics Corporation (BBLG).
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Bone Biologics Corporation (BBLG)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and healthcare professionals.
- Comprehensive Data: Bone Biologics' historical and projected financials are preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing Bone Biologics Corporation (BBLG) investments.
- Biotech Research Teams: Evaluate valuation scenarios to inform research and development strategies.
- Financial Consultants: Offer clients precise valuation insights for Bone Biologics Corporation (BBLG) stock.
- Students and Educators: Utilize real-world data to learn and teach financial modeling in the biotech sector.
- Industry Analysts: Gain insights into how biotech companies like Bone Biologics Corporation (BBLG) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: Bone Biologics Corporation’s (BBLG) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Bone Biologics Corporation’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.